We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Products Released for Forensic Drug Testing in Laboratories Worldwide

By LabMedica International staff writers
Posted on 17 Feb 2011
A global diagnostic company has released a number of new products for forensic drug testing in public and private laboratories worldwide.

A Drugs of Abuse array (DoA I+) enables all tests to be measured simultaneously from a single sample. More...
Tests available include; amphetamine, methamphetamine, barbiturates, benzodiazepine 1 and 2, cannabinoids, cocaine metabolite, methadone, opiates and phencyclidine, buprenorphine, fentanyl, generic opioids, ketamine, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA, also known as ecstasy), methaqualone, oxycodone 1 and 2, propoxyphene, buprenorphine, and tricyclic antidepressants (TCAs).

Randox (Crumlin, United Kingdom) Biochip array technology has created a reduction for time spent on individual tests. A number of drug analytes are grouped and carried out on a biochip to allow for consolidated testing. The multimarker process allows toxicologists to determine a substantial amount of information from a small volume of sample. The technology incorporates enzyme-linked immunosorbent assay (ELISA) principles, providing accurate and reliable results.

Antibodies are manufactured by Randox onsite allowing the company to sustain quality while continually expanding its test portfolio. Drug testing solutions are also offered for clinical toxicology, workplace drug testing, and onsite testing environments. Randox manufactures high quality diagnostic products for laboratories worldwide.

Related Links:
Randox



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Immunofluorescence Analyzer
IFA System
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.